Stocks股票 / Health Care / NEO
NEO US listed · USD美股 · 美元
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing.NeoGenomics Laboratories, Inc.,亦称 NeoGenomics 或 Neo,是一家美国CLIA认证的临床实验室、制药服务和信息服务公司,专门从事癌症遗传学诊断检测。
Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-07-21Earnings财务业绩
next report下次财报 2026-08-04Estimates being raised — 6 analysts预期上调 — 6 位分析师
Valuation估值
Roughly fair vs sector相对行业估值合理| Multiple指标 | NEO | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/B市净率 | 2.20x | 3.44 | |
| Earnings yield盈利收益率 | -5.88% | 2.72 | |
| FCF yield自由现金流收益率 | -1.19% | 4.00 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$0.6M net (0 buyers, 2 sellers)-$0.6M 净值(0 买家,2 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing.NeoGenomics Laboratories, Inc.,亦称 NeoGenomics 或 Neo,是一家美国CLIA认证的临床实验室、制药服务和信息服务公司,专门从事癌症遗传学诊断检测。
- Margin compression despite revenue growth
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| Price / Book市净率 | 2.2× | 3.4× | 70% |
| Earnings yield盈利收益率 | -5.9% | 2.7% | 14% |
| Free-cash-flow yield自由现金流收益率 | 0.3% | 5.5% | 10% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +0.9% | -0.9% |
| 1 Month近1月 | +27.9% | -0.6% |
| 3 Months近3月 | +78.9% | +5.4% |
| 6 Months近6月 | +12.2% | +8.6% |
| Year to date年初至今 | +21.1% | +8.9% |
| 1 Year近1年 | +128.2% | +19.2% |
| 3 Years近3年 | -18.3% | +69.9% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $444M | $484M | $510M | $592M | $661M | $727M |
| EPS每股收益 | — | — | — | — | — | — |
| Free cash flow自由现金流 | $-28M | $-91M | $-97M | $-31M | $-34M | $-22M |
| Gross margin毛利率 | 41.8% | 38.6% | 36.9% | 41.3% | 43.9% | 43.2% |
| Net margin净利率 | 0.9% | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
| FCF margin自由现金流利润率 | -6.2% | -18.8% | -19.0% | -5.2% | -5.2% | -3.0% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: earnings cash-backed盈利质量:盈利有现金支撑
- Working capital: working capital roughly in line with sales营运资本:营运资本与销售大致同步
- Pricing power: gross margin +1.4pts over 6 years定价能力:毛利率 6 年上升 1.4 个百分点
- Capital discipline: share count +22.3% over 6 years (dilution)资本纪律:股本 6 年增加 22.3%(稀释)
- Balance sheet: Altman Z 2.17 — grey zone资产负债表:Altman Z 2.17——灰色区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Estimate revisions预期修正
Insiders & shorts内部人与空头
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 33% | -8.0% | 3 |
| Feb2月 | 33% | -19.3% | 3 |
| Mar3月 | 33% | -1.4% | 3 |
| Apr4月 | 33% | -10.9% | 3 |
| May5月 | 67% | +13.7% | 3 |
| Jun6月 | 75% | +1.7% | 4 |
| Jul7月 | 50% | +8.6% | 4 |
| Aug8月 | 33% | -6.2% | 3 |
| Sep9月 | 0% | -11.4% | 3 |
| Oct10月 | 67% | +14.5% | 3 |
| Nov11月 | 100% | +27.5% | 3 |
| Dec12月 | 0% | -6.7% | 3 |